Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISOLDA influenza and COVID-19 vaccine co-administration study in older adults
NL-OMON59351Phase 2Completed
- Sponsor
- CR2O
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of ARCT-2138 in coronavirus disease 2019 (COVID-19) and influenza (3 arms), sponsored by CR2O. Primary endpoints: Serum neutralizing antibody response to SARS-CoV-2 variants of concern, Change in geometric mean titres of anti-SARS-CoV-2 spike binding antibodies and 1 more. Started Oct 2024; status: completed.
02
Drugs
ARCT-2138
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NL-OMON59351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59351.